Lyell Immunopharma, Inc. — Director's Dealing 2025

Mar 19, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2025-03-14

Reporting Person: Klausner Richard (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-03-14	Common Stock	P	158000	$0.6009	Acquired	843365	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2967834	Direct

Footnotes

F1: The price reported above reflects the weighted average price of the shares purchased. These shares were purchased in multiple transactions at prices ranging from $0.59 to $0.62, inclusive. Upon request from the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this range.

F2: Consists of 158,000 shares held by The Klausner Family Revocable Trust of May 8, 2014, 245,515 shares held by The Ariella Klausner Delaware Trust, 194,335 shares held by The Eli Klausner Delaware Trust and 245,515 shares held by The Olivia Klausner Delaware Trust (collectively, The Ariella Klausner Delaware Trust, The Eli Klausner Delaware Trust and The Olivia Klausner Delaware Trust, the "Delaware Trusts"). The Reporting Person is grantor and trustee of The Klausner Family Revocable Trust of May 8, 2014 and grantor of each of the Delaware Trusts. The JTC Trust Company (Delaware) Limited is the trustee of each of the Delaware Trusts. The Reporting Person disclaims beneficial ownership of all shares held by the Delaware Trusts except to any pecuniary interest therein.